Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma.

Michael Asger Andersen,Rebecca Valentin,Lene Dissing Sjö,Line Borgwardt,Kjeld Schmiegelow,Mette K. Andersen,Rasmus Lykke Marvig,Christina W. Yde,Carsten Utoft Niemann

Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma.

2020

Michael Asger Andersen
Rebecca Valentin
Lene Dissing Sjö
Line Borgwardt
Kjeld Schmiegelow
Mette K. Andersen
Rasmus Lykke Marvig
Christina W. Yde
Carsten Utoft Niemann

T-prolymphocytic leukemia (T-PLL) is a rare, mature T-cell leukemia representing less than 2% of mature lymphocytic leukemias [1,2]. T-PLL is generally resistant to conventional chemotherapy with a...

Keywords:

Cancer research
T cell
Epigenetic therapy
Lymphoma
Venetoclax
Alemtuzumab
Lymphoblastic Leukemia
T-cell prolymphocytic leukemia
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations